Skip to main content
. 2021 Nov 2;15(1):116–122. doi: 10.1016/j.jiph.2021.10.024

Fig. 2.

Fig. 2

PaO2/FiO2 (P/F) ratio before and after receiving therapy (data are expressed as mean ± SE. TCZ-HCQ; tocilizumab plus hydroxychloroquine treatment group, TCZ-RMV; tocilizumab plus remdesivir treatment group.

(*) significantly different when compared with baseline P/F ratio before receiving TCZ-HCQ at p < 0.001.

(#) significantly different when compared with baseline P/F ratio before receiving TCZ-RMV at p < 0.001.